MAGE-A3 expression in patients screened for the DERMA trial: A phase III trial testing MAGE-A3 immunotherapeutic in the adjuvant setting for stage IIIB-C-Tx melanoma.
John F Thompson
Consultant or Advisory Role - GlaxoSmithKline (U)
Honoraria - GlaxoSmithKline
Mario Santinami
No relevant relationships to disclose
Thomas Jouary
Honoraria - Bristol-Myers Squibb
Eugeny Levchenko
No relevant relationships to disclose
Bernard Mark Smithers
No relevant relationships to disclose
Laurent Mortier
No relevant relationships to disclose
Jean Jacques Grob
Consultant or Advisory Role - GlaxoSmithKline
Honoraria - GlaxoSmithKline
Uwe Trefzer
Consultant or Advisory Role - GlaxoSmithKline
Ralf Gutzmer
Consultant or Advisory Role - Almirall Hermal GmbH; Bristol-Myers Squibb; GlaxoSmithKline; Merck Sharp & Dohme; Novartis
Honoraria - Almirall Hermal GmbH; Anigen; Bristol-Myers Squibb; GlaxoSmithKline; Merck Serono; Roche
Research Funding - Novartis; Roche
Other Remuneration - Bristol-Myers Squibb; Merck Sharp & Dohme; Roche
Corinne Jamoul
Employment or Leadership Position - GlaxoSmithKline
Olivier Peeters
Employment or Leadership Position - GlaxoSmithKline
Brigitte Dreno
Consultant or Advisory Role - GlaxoSmithKline
John M. Kirkwood
Consultant or Advisory Role - Genentech; GlaxoSmithKline